Bern, Switzerland, Thursday, January 26, 2023 - CIS Pharma attends the first Swiss RNA Therapeutics Summit in Bern. The Summit brings together stakeholders in the field of RNA Therapeutics from academia, biotechnology, pharma, manufacturing, [...]
Bubendorf, Switzerland, Tuesday, January 24, 2023 – CIS Pharma engages additional resources in 2023 to develop a novel linker/carrier system to conjugate ASO and siRNA for targeted delivery. To widen the therapeutic use of [...]
Bubendorf, Switzerland, Wednesday, January 18, 2023 - CIS Pharma has identified its lead anti-B7H3 nanobody displaying promising affinity to the target. The production of the final candidate is up-scaled and the nanobody is labeled [...]
Bubendorf, Switzerland, Tuesday, December 20, 2022 - CIS Pharma has successfully tested its anti-L1CAM radioligand against ovarian cancer in a Xenograft mouse model. The antibody-based radioligand comprises chelators conjugated to the antibody site-sepcifically. Labeled [...]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.